Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Dec;70(12):8858-64.
doi: 10.1128/JVI.70.12.8858-8864.1996.

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus

Affiliations
Free PMC article

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus

B M Kerr et al. J Virol. 1996 Dec.
Free PMC article

Abstract

Persistent Epstein-Barr virus (EBV) infection is primarily controlled by HLA class I-restricted memory cytotoxic T-cell (CTL) responses which can be reactivated in vitro by stimulation of peripheral blood lymphocytes with autologous lymphoblastoid cell lines. During an investigation of a donor infected by both type A and type B EBV, CTL specific for type B EBV were isolated. The CTL were found to recognize an epitope encoded by the EBNA-6B gene. The minimal epitope sequence was identified as QNGALAINTF, corresponding to residues 213 to 222 in the EBNA-6B protein, and presentation of this epitope was shown to be via HLA B62 (B15). This is the first report of the characterization of an epitope that is EBV type B specific. CTL recognizing sequences common to type A and type B EBV were identified as well. A cross-reactive epitope recognized by these CTL was encoded within the EBNA-6 gene of both type A and type B. This minimal sequence for this epitope was LLDFVRFMGV (residues 284 to 293 in both types), and the epitope was restricted through HLA A*0201. This second epitope sequence overlaps with a published EBV B44-restricted epitope (EENLLDFVRF). The implications of these findings are discussed with respect to the design and efficacy of epitope-based vaccines.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int J Cancer. 1987 Apr 15;39(4):472-6 - PubMed
    1. Scand J Immunol. 1987 Jan;25(1):21-8 - PubMed
    1. Nature. 1988 Feb 25;331(6158):719-21 - PubMed
    1. Virology. 1989 Aug;171(2):401-8 - PubMed
    1. Lancet. 1989 Sep 30;2(8666):761-5 - PubMed

Publication types

MeSH terms